11th International Congress on Psychopharmacology & 7th International Symposium on Child and Adolescent Psychopharmacology

References

• Бохан HA. Нейробиологические проблемы изучения аддиктивных расстройств. Сибирский вестник психиатрии и наркологии 2008; 1:59-63.
   Google Scholar
• Abdullaeva VK. Clinical-psychological and pathochemical mechanisms of the opioid addiction of persons with comorbid pathology. ISJ Theoretical & Applied Science 2016; 01(33): 58-63.
   Google Scholar
• Khalsa JH. Medical Consequences of Drug Abuse and Cooccurring Infections: Research at the National Institute on Drug Abuse. Subst. Abus 2008; 29 (3):5-16.
   PubMed Web of Science ®Google Scholar
• Brent D, Mann JJ. Family genetic studies, suicide, and suicidal behavior. Am J Med Genet Part C Semin Med Genet. 2005 Feb 15;133C(1):13–24.
   PubMed Web of Science ®Google Scholar
• Stieg MR, Sievers C, Farr O, Stalla GK, Mantzoros CS. Leptin: A hormone linking activation of neuroendocrine axes with neuropathology. Psychoneuroendocrinology. 2015;51:47–57.
   PubMed Web of Science ®Google Scholar
• Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2018 Feb 16
   Web of Science ®Google Scholar
• Hryhorczuk C, Sharma S, Fulton SE. Metabolic disturbances connecting obesity and depression. Front Neurosci. 2013;7(7 OCT):1–14.
   Google Scholar
• Sambrook J, Fritsch E, Maniatis T. Molecular Cloning: A Laboratory Manual (Fourth Edition). 2nd ed. New York, USA: Cold-Spring Harbor; 1989. 9.16-9.19.
   Google Scholar
• Gotoda T, Manning BS, Goldstone AP, Imrie H, Evans AL, Strosberg AD, et al. Leptin receptor gene variation and obesity: lack of association in a white British male population. Hum Mol Genet. 1997 Jun;6(6):869–76.
   PubMed Web of Science ®Google Scholar
• Jakopec M. Association between LEPR gene 1019 polymorphism and the morphological characteristics in Roma population of Croatia. Master Thesis. 2015.
   Google Scholar
• Suriyaprom K, Tungtrongchitr R, Thawnasom K. Measurement of the levels of leptin, BDNF associated with polymorphisms LEP G2548A, LEPR Gln223Arg and BDNF Val66Met in Thai with metabolic syndrome. Diabetol Metab Syndr. 2014;6(1):6.
   Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Gecici O, Firidin B. Serum leptin and cholesterol values in suicide attempters. Neuropsychobiology. 2002;45(3):124–7.
   PubMed Web of Science ®Google Scholar
• Tutuncu R, Gunay H, Balibey H, Abaslı D. Decreased Leptin Levels in Antisocial Personality Disorder Patients. Klin Psikofarmakol Bülteni-Bulletin Clin Psychopharmacol. 2013 Mar 8;23(1):72–6.
   Web of Science ®Google Scholar
• Fattore L, Fratta W. Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neuroscience. 2011;5(September):1–12.
   Google Scholar
• Cohen K, Kapitány-Fövény M, Mama Y, Arieli M, Rosca P, Demetrovics ZWA. The effects of synthetic cannabinoids on executive function. 2017; 1121-1134.
   Google Scholar
• Yilmaz H, Bozkurt M, Evren C, Umut G, Keskinkilic C. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder. Psychiatry Res. 2018;262(June 2017):46–54.
   Google Scholar
• Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, et al. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology. 2000;23(2):113–126.
   PubMed Web of Science ®Google Scholar
• Pau CWH, Lee TMC, Chan SFF. The impact of heroin on frontal executive functions. Arch Clin Neuropsychol. 2002;17(7):663–670.
   Web of Science ®Google Scholar
• Karakaş S, Erdoğan E, Sak L, Soysal AŞ. Stroop Testi TBAG Formu: Türk Kültürüne Standardizasyon Çalışmaları. Klin Psikiyatr. 1999;75–88.
   Google Scholar
• Karakaş S. (WCST) ve Stroop Testi TBAG formu puanlarının test içi ve testler-arası ilişkileri. X Ulus Psikol Kongresi özet kitabı. 1998;44.
   Google Scholar
• Won E, Kim Y-K. Stress the autonomic nervous system, and the immune-kynurenine pathway in the etiology of depression. Current neuropharmacology. 2016;14(7):665-73.
   PubMed Web of Science ®Google Scholar
• Hochstrasser T, Ullrich T, Sperner-Unterweger B, Humpel C. Inflammatory stimuli reduce survival of serotonergic neurons and induce neuronal expression of indoleamine 2,3-dioxygenase in rat dorsal raphe nucleus organotypic brain slices. Neuroscience. 2011;184: 128-38.
   PubMed Web of Science ®Google Scholar
• Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy states. International Journal of Tryptophan Research. 2009; 2: IJTR. S2097.
   Google Scholar
• Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Archives of general psychiatry. 2011;68(11):1095-102.
   PubMed Web of Science ®Google Scholar
• Caglayan AO. Genetic causes of syndromic and non-syndromic autism. Developmental Medicine & Child Neurology. 2010;52(2):130-8.
   Web of Science ®Google Scholar
• Geschwind DH. Genetics of autism spectrum disorders. Trends in cognitive sciences. 2011;15(9):409-16.
   PubMed Web of Science ®Google Scholar
• Huguet G, Benabou M, Bourgeron T. The Genetics of Autism Spectrum Disorders. In: Sassone-Corsi P, Christen Y, editors. A Time for Metabolism and Hormones. Cham: Springer International Publishing; 2016. p. 101-29.
   Google Scholar
• Anney R, Klei L, Pinto D, Regan R, Conroy J, Magalhaes TR, et al. A genome-wide scan for common alleles affecting risk for autism. Human molecular genetics. 2010;19(20):4072-82.
   Google Scholar
• Chen D, Vollmar M, Rossi MN, Phillips C, Kraehenbuehl R, Slade D, et al. Identification of macrodomain proteins as novel O-acetyl-ADP-ribose deacetylases. The Journal of biological chemistry. 2011;286(15):13261-71.
   Web of Science ®Google Scholar
• Han W, Li X, Fu X. The macro domain protein family: structure, functions, and their potential therapeutic implications. Mutation research. 2011;727(3):86-103.
   Web of Science ®Google Scholar
• Tsang KM, Croen LA, Torres AR, Kharrazi M, Delorenze GN, Windham GC, et al. A genome-wide survey of transgenerational genetic effects in autism. PloS one. 2013;8(10):e76978.
   Web of Science ®Google Scholar
• Curran S, Bolton P, Rozsnyai K, Chiocchetti A, Klauck SM, Duketis E, et al. No association between a common single nucleotide polymorphism, rs4141463, in the MACROD2 gene and autism spectrum disorder. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics. 2011;156b(6):633-9.
   Web of Science ®Google Scholar
• Anney R, Klei L, Pinto D, Almeida J, Bacchelli E, Baird G, et al. Individual common variants exert weak effects on the risk for autism spectrum disorders. Human molecular genetics. 2012;21(21):4781-92.
   PubMed Web of Science ®Google Scholar
• Prandini P, Pasquali A, Malerba G, Marostica A, Zusi C, Xumerle L, et al. The association of rs4307059 and rs35678 markers with autism spectrum disorders is replicated in Italian families. Psychiatric genetics. 2012;22(4):177-81.
   Web of Science ®Google Scholar
• Jones RM, Cadby G, Blangero J, Abraham LJ, Whitehouse AJO, Moses EK. MACROD2 gene associated with autistic-like traits in a general population sample. Psychiatric genetics. 2014;24(6):241-8.
   Web of Science ®Google Scholar
• Kuo PH, Chuang LC, Su MH, Chen CH, Chen CH, Wu JY, et al. Genome-Wide Association Study for Autism Spectrum Disorder in Taiwanese Han Population. PloS one. 2015;10(9):e0138695.
   Web of Science ®Google Scholar
• Namjou B, Marsolo K, Caroll RJ, Denny JC, Ritchie MD, Verma SS, et al. Phenome-wide association study (PheWAS) in EMR-linked pediatric cohorts, genetically links PLCL1 to speech language development and IL5-IL13 to Eosinophilic Esophagitis. Frontiers in genetics. 2014;5:401.
   Web of Science ®Google Scholar
• Torrico B, Chiocchetti AG, Bacchelli E, Trabetti E, Hervas A, Franke B, et al. Lack of replication of previous autism spectrum disorder GWAS hits in European populations. Autism research: official journal of the International Society for Autism Research. 2017;10(2):202-11.
   Web of Science ®Google Scholar
• Consortium AG. Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia. Molecular autism. 2017;8:21.
   Web of Science ®Google Scholar
• Piven J, Elison JT, Zylka MJ. Toward a conceptual framework for early brain and behavior development in autism. Molecular Psychiatry. 2017;23:165.
   Web of Science ®Google Scholar
• Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). Journal of autism and developmental disorders. 1980;10(1):91-103.
   PubMed Web of Science ®Google Scholar
• İncekaş S, Baykara B, Avcil S, Demiral Y. Validity and Reliability Analysis of Turkish Version of Childhood Autism Rating Scale. Turkish Journal of Psychiatry. 2016;27(4).
   Google Scholar
• Sucuoğlu B. The psychometric characteristics of the Turkish form of the aberrant behavior checklist. Turk Psikol Derg. 2003;18:77-9.
   Web of Science ®Google Scholar
• Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nature Protocols. 2008;3:1101.
   Google Scholar
• Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, et al. Spatio-temporal transcriptome of the human brain. Nature. 2011;478(7370):483-9.
   PubMed Web of Science ®Google Scholar
• Ansel A, Rosenzweig JP, Zisman PD, Melamed M, Gesundheit B. Variation in Gene Expression in Autism Spectrum Disorders: An Extensive Review of Transcriptomic Studies. Frontiers in Neuroscience. 2016;10:601.
   PubMed Web of Science ®Google Scholar
• Kessler, RC, et al., Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry, 2005. 62(6): p. 593-602.
   PubMed Web of Science ®Google Scholar
• Kessler, RC. The costs of depression. Psychiatric Clinics, 2012. 35(1): p. 1-14.
   Google Scholar
• Türkçapar, H. Bilişsel terapi: Temel ilkeler ve uygulama. 2009: HYB Yayıncılık, 2002 (Medico Graphics Ofset).
   Google Scholar
• Hoyt, B. D. (2005). Sleep in patients with neurologic and psychiatric disorders. Primary care, 32(2), 535-48.
   Web of Science ®Google Scholar
• Wilson, S., & Argyropoulos, S. (2012). Sleep in schizophrenia: time for closer attention. The British Journal of Psychiatry, 200(4), 273-274.
   Web of Science ®Google Scholar
• YETKİN, S., & AYDIN, H. (2014). Psikotropik İlaçların Uyku Üzerine Etkileri. Turkiye Klinikleri Journal of Psychiatry Special Topics, 7(1), 36-42.
   Google Scholar
• Miller, D. D. (2004). Atypical antipsychotics: sleep, sedation, and efficacy. Primary care companion to the Journal of clinical psychiatry, 6(suppl 2), 3.
   PubMedGoogle Scholar
• Yamashita H, Morinobu S, and Yamawaki S. et al. Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol. Psychiatry Res. 2002 109:137–142. [PubMed]
   PubMed Web of Science ®Google Scholar
• Collaborative Working Group on Clinical Trial Evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. J Clin Psychiatry. 1998 59suppl 12. 3–9.
   Google Scholar
• Idzikowski C, Mills FJ, Glennard R. 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res. 1986;378:164–168
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment followingacute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6 (4): 325-37.
   PubMed Web of Science ®Google Scholar
• Monti, J. M., Torterolo, P., & Perumal, S. R. P. (2017). The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep medicine reviews, 33, 51-57.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Weng Y, Li W et al. Training patients with schizophrenia with the community re-entry module: a controlled study. Soc Psychiatry Psychiatr Epidemiol 2006; 41:464-469.
   PubMed Web of Science ®Google Scholar
• Foruzandeh, N., & Parvin, N. (2013). Occupational therapy for inpatients with chronic schizophrenia: a pilot randomized controlled trial. Japan Journal of Nursing Science, 10(1), 136-141.
   PubMed Web of Science ®Google Scholar
• Perilli, V., Stasolla, F., Maselli, S., & Morelli, I. (2018). Occupational Therapy and Social Skills Training for Enhancing Constructive Engagement of Patients with Schizophrenia: A Review.
   Google Scholar
• Karatay G, Kubilay G. Sosyoekonomik düzeyi farklı iki lisede madde kullanma durumu ve etkileyen faktörlerin belirlenmesi. Hemşirelikte Araştırma Geliştirme Dergisi, 1(2), 57-70, 2004.
   Google Scholar
• Karakaş SA, Ersöğütçü F. Madde Bağımlılığı ve Hemşirelik. Sağlık Bilimleri ve Meslekleri Dergisi, 3(2), 133-139, 2016.
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. (2018). European Drug Report: Trends and Developments, 2018.
   Google Scholar
• Tamar-Gurol D, Sar V, Karadag F, Evren C, Karagoz M. Childhood emotional abuse, dissociation, and suicidality among patients with drug dependency in Turkey. Psychiatry and Clinical Neurosciences, 62(5), 540-547, 2008.
   PubMed Web of Science ®Google Scholar
• Bilici R, Beker ŞD, Süner Ö, Çıtak S, Izci F. Sociodemographic characteristics of Turkish patients who violated a supervised probation program. Journal of ethnicity in substance abuse, 17(3), 335-344, 2018.
   Web of Science ®Google Scholar
• Şıpka H, Sönmez B, Karaca E, Vardar E. Bir üniversite hastanesi bağımlılık merkezinde yatarak tedavi gören hastaların profili: Bir yıllık AMATEM verilerinin incelenmesi. 50. Ulusal Psikiyatri Kongresi. Turk Psikiyatri Derg, 25, 32; 2014.
   Google Scholar
• Bulut M, Savaş HA, Cansel N, Selek S, Kap Ö, Yumru M, Vırıt O. Gaziantep Üniversitesi Alkol Ve Madde Kullanim Bozukluklari Birimine Başvuran Hastalarin Sosyodemografik Özellikleri. Journal of Dependence, 7, 65-70; 2006.
   Google Scholar
• Çakmak D, Kralı A, Akvandaz Y. Son beş yıl içinde AMATEM’e yatan bağımlıların özellikleri. 1996.
   Google Scholar
• Alpay N, Maner F, Kalyoncu A. AMATEM’de 1990 yılında yatırılan madde bağımlılarının demografik özellikleri ve geçmiş yıllarla kıyaslanması. 27. Ulusal Psikiyatri Kongresi Program ve Bildiri Özetleri Kitabı, 177. 1991
   Google Scholar
• Türkiye Uyuşturucu ve Uyuşturucu Bağımlılığı İzleme Merkezi. Türkiye Uyuşturucu Raporu. Ankara: Yazar. 2018.
   Google Scholar
• Galea S, Vlahov D. Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public health reports, 117(Suppl 1), S135. 2002.
   PubMed Web of Science ®Google Scholar
• Sherba RT, Coxe KA, Gersper BE, Linley JV. Employment services and substance abuse treatment. Journal of substance abuse treatment, 87, 70-78; 2018.
   PubMed Web of Science ®Google Scholar
• Arria AM, Topps-II Interstate Cooperative Study Group. Drug treatment completion and post-discharge employment in the TOPPS-II interstate cooperative study. Journal of Substance Abuse Treatment, 25(1), 9–18. 2003.
   PubMed Web of Science ®Google Scholar
• Vaillant GE. What can long-term follow-up teach us about relapse and prevention of relapse in addiction? British Journal of Addiction, 83(10), 1147–1157. 1988.
   PubMedGoogle Scholar
• Ritter A, Cameron J. A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug and Alcohol Review, 25(6), 611–624. 2006.
   PubMed Web of Science ®Google Scholar
• Harrison PA, Asche SE. Outcomes monitoring in Minnesota: treatment implications, practical limitations. Journal of Substance Abuse Treatment, 21(4), 173-183. 2001.
   PubMed Web of Science ®Google Scholar
• Manuel JI, Yuan Y, Herman DB, Svikis DS, Nichols O, Palmer E, Deren S. Barriers and facilitators to successful transition from long-term residential substance abuse treatment. Journal of Substance Abuse Treatment, 74, 16–22. 2017
   PubMed Web of Science ®Google Scholar
• Ahern J, Stuber J, Galea S. (2007). Stigma, discrimination and the health of illicit drug users. Drug and Alcohol Dependence, 88(2-3), 188–196. 2007.
   PubMed Web of Science ®Google Scholar
• Ertüzün E, Uyaroğlu AK, Demirel B, Koçak E. Boş Zaman Aktivitelerinin Madde Bağımlılığı Sürecindeki Rolüne İlişkin Nitel Bir Çalışma. Spor Bilimleri Dergisi, 27(2), 49-58. 2016.
   Google Scholar
• Gundogmus, İ., Algul, A., Karagöz, A. and Kıyançiçek, M. PDW and RDW are new parameters for bipolar episodes and unipolar depression. Psychiatry and Clinical Psychopharmacology 2018;4: 1-7.
   Web of Science ®Google Scholar
• Erzin, G., Kotan, V.O., Topçuoğlu, C., Özkaya, G., Erel, Ö., Yüksel, R.N., Ürer, E., Aydemir, M.Ç. and Göka, E. Thiol/disulphide homeostasis in bipolar disorder. Psychiatry research 2018;261: 237-242.
   PubMed Web of Science ®Google Scholar
• Usta, M.B., Karabekiroglu, K., Sahin, B., Aydin, M., Bozkurt, A., Karaosman, T., Aral, A., Cobanoglu, C., Kurt, A.D., Kesim, N. and Sahin, İ., 2018. Use of machine learning methods in prediction of short-term outcome in autism spectrum disorders. Psychiatry and Clinical Psychopharmacology 2018;16:1-6.
   Web of Science ®Google Scholar
• Soygür H. Psikofarmakolojinin Tarihsel Gelişimi. Yüksel N, editor. Temel Psikofarmakoloji. Ankara: Türkiye Psikiyatri Derneği Yayınları; 2010. s: 1–15.
   Google Scholar
• Glennon J, Purper-Ouakil D, Bakker M, et al. Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. Eur Child Adolesc Psychiatry. 2014;23(12):1149–1160. Published online 2013 Dec 15.
   Web of Science ®Google Scholar
• Arabgol F, Panaghi L, Nikzad V. Risperidone versus Methylphenidate in Treatment of Preschool Children With Attention-Deficit Hyperactivity Disorder. Iran J Pediatr. 2015 Feb;25(1):e265. Published online 2015 Feb 21.
   PubMed Web of Science ®Google Scholar
• Garfield LD, Brown DS, Allaire BT, Ross RE, Nicol GE, Raghavan R. Psychotropic Drug Use Among Preschool Children in the Medicaid Program From 36 States. Am J Public Health. 2015 March;105(3):524–529. Published online 2015 March. doi: 10.2105/AJPH.2014.302258
   Web of Science ®Google Scholar
• Johnston AN, Bu W, Hein S, Garcia S, Camacho L, Xue L, et al. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018;20:42. Published online 2018 May 19.
   Web of Science ®Google Scholar
• Corkum P, Tannock R, Moldofsky H. Sleep disturbances in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1998;37:637–646.
   PubMed Web of Science ®Google Scholar
• Miano S, Parisi P, Villa MP. The sleep phenotypes of attention deficit hyperactivity disorder: The role of arousal during sleep and implications for treatment. Medical Hypotheses 2012;79:147–153.
   Web of Science ®Google Scholar
• Weiss MD, Salpekar J. Sleep problems in the child with attention-deficit hyperactivity disorder. CNS drugs. 2010;24(10):811–828.
   PubMed Web of Science ®Google Scholar
• Corbetta M, Patel G, Shulman GL. The reorienting system of the human brain: from environment to theory of mind. Neuron 2008;58(3):306–324.
   PubMed Web of Science ®Google Scholar
• Eklund A, Nichols TE, Knutsson H. Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci U S A 2016;113(28):7900–7905.
   PubMed Web of Science ®Google Scholar
• Kim BN, Lee JS, Shin MS, Cho SC, Lee DS. Regional cerebral perfusion abnormalities in attention deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2002;252(5):219–225.
   PubMed Web of Science ®Google Scholar
• Lee JS, Kim BN, Kang E, Lee DS, Kim YK, Chung JK, Lee MC, Cho SC. Regional cerebral blood flow in children with attention deficit hyperactivity disorder: comparison before and after methylphenidate treatment. Human Brain Mapp. 2005;24(3):157–164.
   PubMed Web of Science ®Google Scholar
• O’Gorman RL, Mehta MA, Asherson P, Zelaya FO, Brookes KJ, Toone BK, Alsop DC, Williams SC. Increased cerebral perfusion in adult attention deficit hyperactivity disorder is normalised by stimulant treatment: a non-invasive MRI pilot study. Neuroimage 2008;42(1):36–41.
   PubMed Web of Science ®Google Scholar
• Uzbay TI. Pharmacological importance of agmatine in brain. Neurosci Biobehav Rev. 2012; 36:502–519.
   PubMed Web of Science ®Google Scholar
• Uzbay T. A new target for diagnosis and treatment of CNS disorders: Agmatinergic system. Curr Med Chem. 2012b;19:5116–5121.
   Web of Science ®Google Scholar
• Reis DJ, Regunathan S. Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J Auton Nerv Syst. 1998;72:80–85.
   Google Scholar
• Madai VI, Poller WC, Peters D, et al. Synaptic localisation of agmatinase in rat cerebral cortex revealed by virtual pre-embedding. Amino Acids. 2012;43:1399–1403.
   Web of Science ®Google Scholar
• Halaris A, Plietz J. Agmatine. CNS drugs. 2007;21:885–900.
   PubMed Web of Science ®Google Scholar
• Auguet M, Viossat I, Marin JG, Chabrier PE. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol. 1995;69:285–287.
   PubMedGoogle Scholar
• Feng Y, LeBlanc MH, Regunathan S. Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects. Neurosci Lett. 2005;390:129–133.
   PubMed Web of Science ®Google Scholar
• Galea E, Regunathan S, Eliopoulos V, Feinstein DL. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J. 1996;316:247–249.
   PubMed Web of Science ®Google Scholar
• Wang WP, Iyo AH, Miguel-Hidalgo J, Regunathan S, Zhu MY. Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res. 2006;1084:210–216.
   PubMed Web of Science ®Google Scholar
• Wang XF, Wu N, Su RB, Lu XQ, Liu Y, Li J. Agmatine modulates neuroadaptations of glutamate transmission in the nucleus accumbens of repeated morphine-treated rats. Eur J Pharmacol. 2011;650:200–205.
   Web of Science ®Google Scholar
• Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301–1308.
   PubMed Web of Science ®Google Scholar
• Treen D, Batlle S, Mollà L, et al. Are there glutamate abnormalities in subjects at high risk mental state for psychosis? A review of the evidence. Schizophren Res. 2016;171:166–175.
   Web of Science ®Google Scholar
• Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry. 2002;59:553–558.
   PubMed Web of Science ®Google Scholar
• Yao JK, Leonard S, Reddy RD. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophren Bull. 2004;30:923–934.
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid Redox Signal. 2001;15:1999–2002.
   Web of Science ®Google Scholar
• Shim S, Shuman M, Duncan E. An emerging role of cGMP in the treatment of schizophrenia: a review. Schizophren Res. 2016;170:226–231.
   Web of Science ®Google Scholar
• Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 1991;14:60–67.
   PubMed Web of Science ®Google Scholar
• Uzbay IT, Oglesby MW. Nitric oxide and substance dependence. Neurosci Biobehav Rev. 2001;25:43–52.
   PubMed Web of Science ®Google Scholar
• Hallak JE, Maia-de-Oliveira JP, Abrao J, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 2013;70:668–676.
   PubMed Web of Science ®Google Scholar
• Liu P, Jing Y, Collie ND, Dean B, Bilkey DK, Zhang H. Altered brain arginine metabolism in schizophrenia. Transl Psychiatry. 2016;6:e871.
   PubMed Web of Science ®Google Scholar
• Uzbay T, Kayir H, Goktalay G, Yildirim M. Agmatine disrupts prepulse inhibition of acoustic startle reflex in rats. J Psychopharmacol. 2010;24:923–929.
   Web of Science ®Google Scholar
• Kotagale NR, Taksande BG, Wadhwani PJ, et al. Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents. Pharmacol Biochem Behav. 2012;100:398–403.
   Web of Science ®Google Scholar
• Pålsson E, Fejgin K, Wass C, Klamer D. Agmatine attenuates the disruptive effects of phencyclidine on prepulse inhibition. Europ J Pharmacol. 2008;590:212–216.
   Web of Science ®Google Scholar
• Uzbay T, Goktalay G, Kayir H, et al. Increased plasma agmatine levels in patients with schizophrenia. J Psychiatric Res. 2013;47:1054–1060.
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013.
   Google Scholar
• Yang KC, Reis DJ. Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J Pharmacol Exp Ther. 2004;288:544–549.
   Google Scholar
• Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002;42:165–791.
   PubMed Web of Science ®Google Scholar
• Lindsley CW, Shipe WD, Wolkenberg SE, et al. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem. 2006;6:771–785.
   PubMed Web of Science ®Google Scholar
• Harrison PJ. Metabotropic glutamate receptor agonists for schizophrenia. Br J Psychiatry. 2008;192:86–87.
   PubMed Web of Science ®Google Scholar
• Knox LT, Jing Y, Collie ND, Zhang H, Liu P. Effects of acute phencyclidine administration on arginine metabolism in the hippocampus and prefrontal cortex in rats. Neuropharmacol. 2014;81:195–205.
   Web of Science ®Google Scholar
• Djordjević VV, Stojanović I, Stanković-Ferlež D, et al. Plasma nitrite/nitrate concentrations in patients with schizophrenia. Clin Chem Lab Med. 2010;48:89–94.
   Web of Science ®Google Scholar
• Yilmaz N, Herken H, Cicek HK, Celik A, Yürekli M, Akyol Ö. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princip Practic. 2007;16:137–141.
   PubMed Web of Science ®Google Scholar
• Baba H, Suzuki T, Arai H, Emson PC. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 2004;15:677–680.
   PubMed Web of Science ®Google Scholar
• Lauer M, Johannes S, Fritzen S, Senitz D, Riederer P, Reif A. Morphological abnormalities in nitric-oxide-synthase-positive striatal interneurons of schizophrenic patients. Neuropsychobiol. 2005;52:111–117.
   Web of Science ®Google Scholar
• Gupta N, Jing Y, Collie ND, Zhang H, Liu P. Ageing alters behavioural function and brain arginine metabolism in male Sprague–Dawley rats. Neuroscience. 2012;226:178–196.
   Web of Science ®Google Scholar
• Rushaidhi M, Jing Y, Kennard JT, et al. Aging affects l-arginine and its metabolites in memory-associated brain structures at the tissue and synaptoneurosome levels. Neurosci. 2012;209:21–31.
   Web of Science ®Google Scholar
• Liu P, Zhang H, Devaraj R, Ganesalingam GS, Smith PF. A multivariate analysis of the effects of aging on glutamate, GABA and arginine metabolites in the rat vestibular nucleus. Hearing Res. 2010;269:122–133.
   Web of Science ®Google Scholar
• Liu P, Chary S, Devaraj R, et al. Effects of aging on agmatine levels in memory-associated brain structures. Hippocampus. 2008;18:853–856.
   Web of Science ®Google Scholar
• Esnafoglu E, Irende I. Decreased plasma agmatine levels in autistic subjects. J Neural Transmiss. 2018;125:735–740.
   Web of Science ®Google Scholar
• Chen GG, Almeida D, Fiori L, Turecki G. Evidence of reduced agmatine concentrations in the cerebral cortex of suicides. Int J Neuropsychopharmacol. 2018; doi: 10.1093/ijnp/pyy058
   Web of Science ®Google Scholar
• Maia-de-Oliveira JP, Lobão-Soares B, Ramalho T, et al. Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week. Schizophr Res. 2015;162:211–215.
   PubMed Web of Science ®Google Scholar
• Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg PB, Fearing K. Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol. 1997;20:357–363.
   PubMed Web of Science ®Google Scholar
• Goodwin RD, et al., Epidemiology of Mood Disorders. 2006.
   Google Scholar
• Simon GE, et al., An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341(18):1329–1335.
   PubMed Web of Science ®Google Scholar
• Terre L, et al., Do somatic complaints predict subsequent symptoms of depression? Psychother Psychosom. 2003;72(5):261–267.
   Web of Science ®Google Scholar
• Pennebaker JW. Emotion, disclosure, and health: An overview. 1995.
   Google Scholar
• Hirokawa K, Yagi A, Miyata Y. An examination of the effects of stress management training for Japanese college students of social work. Int J Stress Manag. 2002;9(2):113–123.
   Web of Science ®Google Scholar
• American Psychiatric Association. Attention-deficit/hyperactivity disorder. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013. p. 59.
   Google Scholar
• DuPaul GJ, Stoner G. ADHD in the Schools. Assessment and Intervention Strategies. New York: Guilford Press; 2003.
   Google Scholar
• Uzbay İT. Bağımlılık yapan maddeler ve özellikleri. MİSED (Türk Eczacıları Birliği Meslek İçi Sürekli Eğitim Dergisi). 2009;Aralık(21-22):16–33.
   Google Scholar
• Türkcan A. Alkolün Biyolojik Etkileri, Farmakolojisi, Emilimi, Dağılımı, Metabolizması ve Organ Sistemleri Üzerine Etkileri. Turkiye Klinikleri J Psychiatry Special Top. 2010;3(3):30–36.
   Google Scholar
• İT U. Alkol, Farmakolojik özellikleri ve alkol bağımlılığının nörofarmakolojik yönü. Ege Psikiyatri Sürekli Yayınları (Alkol kullanım bozuklukları ve tedavisi). 1996;1(2):227–254.
   Google Scholar
• Türkyılmaz M, Özsüt H. Direnci Azalmış Konaklarda Görülen İnfeksiyonlar:Alkol Bağımlılarında Görülen İnfeksiyonlar ve Ateş. Klimik Dergisi. 2018;31:145–148.
   Google Scholar
• Kilic E, Rezvani A, Toprak AE, Erman H, Ayhan SK, Poyraz E, et al. Evaluation of neutrophil to lymphocyte and platelet to lymphocyte ratios in rheumatoid arthritis. Dicle Med J. 2016;43(2):241–247.
   Google Scholar
• Yilmaz A, Can Y, Bozkurt M, Evren C. Alkol ve Madde Bagimliliginda Remisyon ve Depresme/Remission and Relapse in Alcohol and Substance Addiction. Psikiyatride Guncel Yaklasimlar. 2014;6(3):243.
   Google Scholar
• Guzel D, Yazici AB, Yazici E, Erol A. Alterations of the hematologic cells in synthetic cannabinoid users. J Clin Lab Anal. 2017;31(6):e22131.
   PubMed Web of Science ®Google Scholar
• Guzel D, Yazici AB, Yazici E, Erol A. Evaluation of Immunomodulatory and Hematologic Cell Outcome in Heroin/Opioid Addicts. J Addict. 2018;2018:2036145. PubMed PMID: 30631635.
   Google Scholar
• Jesse S, Brathen G, Ferrara M, Keindl M, Ben-Menachem E, Tanasescu R, et al. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand. 2017 Jan;135(1):4–16. PubMed PMID: 27586815. Pubmed Central PMCID: PMC6084325. Epub 2016/09/03. eng.
   PubMed Web of Science ®Google Scholar
• Becker HC. Alcohol dependence, withdrawal, and relapse. Alcohol Res Health J Natl Inst Alcohol Abuse Alcohol. 2008;31(4):348–361. PubMed PMID: 23584009.
   PubMedGoogle Scholar
• Antonopoulos, CN, Kadoglou, NP, 2016. Biomarkers in silent traumatic brain injury. Curr Pharm Des. 22, 680-7.
   Web of Science ®Google Scholar
• Al-Ayadhi, LY, Mostafa, GA., 2012. A lack of association between elevated serum levels of S100B protein and autoimmunity in autistic children. J Neuroinflammation. 16, 9-54.
   Google Scholar
• Nelson, PG., Kuddo, T, Song, EY, Dambrosia, JM, Kohler, S, Satyanarayana, G, Vandunk, C, Grether, JK, Nelson, KB, 2006. Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome. Int J Dev Neurosci. 24,73-80.
   PubMed Web of Science ®Google Scholar
• Mabunga DF, Gonzales EL, Kim JW, Kim KC, Shin CY. Exploring the Validity of Valproic Acid Animal Model of Autism. Exp Neurobiol 2015;24(4):285-300.
   PubMed Web of Science ®Google Scholar
• Crawley JN. Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol 2007;17(4):448-59.
   Google Scholar
• Wink LK, Adams R, Horn PS, Tessier CR, Bantel AP, Hong M, et al. A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder. J Autism Dev Disord 2018;48(9):3051-3060.
   PubMed Web of Science ®Google Scholar